Enzo Biochem Long Term Debt

Enzo Biochem (ENZ) currently reports a long-term debt of $2M as of April 2025. That compares with $180K in the prior-year period — up 1038.3% year over year. Use the charts on this page to explore Enzo Biochem's long-term debt history and peer comparisons.

Enzo Biochem's long-term debt increased from $180K to $2M — a 1038.3% year-over-year increase (period ending April 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enzo Biochem reported $2M in long-term debt as of April 2025. That compares with $180K in the prior-year period — up 1038.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Enzo Biochem, and consider following ENZ for alerts when major investors trade the stock.

Enzo Biochem is classified in the Healthcare sector. On long-term debt, it currently shows $2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ENZ with unrelated industries.